1. Home
  2. BW vs IPHA Comparison

BW vs IPHA Comparison

Compare BW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$5.43

Market Cap

544.4M

Sector

Industrials

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.71

Market Cap

174.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BW
IPHA
Founded
1867
1999
Country
United States
France
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
544.4M
174.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BW
IPHA
Price
$5.43
$1.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.50
$5.00
AVG Volume (30 Days)
2.8M
26.1K
Earning Date
11-04-2025
09-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$721,285,000.00
$14,839,695.00
Revenue This Year
N/A
$22.29
Revenue Next Year
$4.85
$43.90
P/E Ratio
N/A
N/A
Revenue Growth
80.30
N/A
52 Week Low
$0.22
$1.60
52 Week High
$7.77
$2.63

Technical Indicators

Market Signals
Indicator
BW
IPHA
Relative Strength Index (RSI) 49.97 40.94
Support Level $4.73 $1.63
Resistance Level $5.44 $1.81
Average True Range (ATR) 0.48 0.08
MACD -0.08 -0.01
Stochastic Oscillator 45.10 35.48

Price Performance

Historical Comparison
BW
IPHA

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: